Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 07 2015 - 7:30AM
Business Wire
Presentation to be Webcast on January 14 at
11:00 A.M. PT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will present a corporate overview that will include an
update on Enanta’s development pipeline, including preclinical data
from Enanta’s new research program in non-alcoholic steatohepatitis
(NASH), on January 14, 2015 at 11:00 a.m. PT during the 33rd Annual
J.P. Morgan Healthcare Conference in San Francisco.
A live webcast and replay of the presentation, as well as of the
question and answer breakout session that follows the presentation,
can be accessed by visiting the “Calendar of Events” section on the
“Investors” page of Enanta’s website at www.enanta.com. The replay
webcast will be available following the presentation and will be
archived for approximately 60 days.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta is discovering, and in some cases developing, novel
inhibitors designed for use against the hepatitis C virus (HCV).
These inhibitors include members of the direct acting antiviral
(DAA) inhibitor classes – protease (partnered with AbbVie), NS5A,
and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Enanta’s lead
protease inhibitor, paritaprevir, is part of AbbVie’s recently
approved HCV treatment regimen. In addition, Enanta has a
preclinical program in non-alcoholic steatohepatitis, or NASH,
which is a condition that results in liver inflammation and damage
caused by a buildup of fat in the liver.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024